The Cancer Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: April 2016
Number of Pages: 223
Number of Tables and Figures: 52

Synopsis: Often cited as one of the leading causes of death worldwide, cancer refers to a group of diseases that are characterized by unrestrained or unregulated growth of cells leading to the formation of malignant tumors that can invade other parts of the body and eventually impair normal functions. 

The prevalence of cancer is continuing to grow, with approximately 15 Million new cases globally each year. However, several immunotherapy and targeted treatments have significantly improved patient outcomes and survival rates. The market is ripe for future growth with a number of targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors. 

As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 9% between 2016 and 2020, eventually accounting for nearly $120 Billion in revenue.

The “Cancer Drugs Market: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the cancer drugs ecosystem including treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for cancer drugs from 2016 through to 2030. The forecasts are segmented for 2 therapeutic pathways, 11 therapeutic categories, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.



For a sample of the report or any further inquiries please contact info@snstelecom.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500


Key Findings:
The report has the following key findings:
  • As new drugs continue to revitalize the cancer treatment ecosystem, we expect the cancer drugs market to grow at a CAGR of 9% between 2016 and 2020, eventually accounting for nearly $120 Billion in revenue.
  • The market is ripe for future growth with a number of targeted therapies in late-stage development, such as PD-1/PD-L1 inhibitors.
  • Another key area of focus for future drug development is CAR-T (Chimeric Antigen Receptor T-Cell) therapy, which involves engineering immune cells to recognize and attack their tumors.
  • The industry continues to witness consolidation in the form of both acquisitions and mergers. Strategic collaborations are also rife in the ecosystem. For example, Swiss cancer drugs giant Roche has formed partnerships with Kite Pharma and Johnson & Johnson to explore combinations using its experimental drug Atezolizumab. 
Topics Covered:
The report covers the following topics:
  • Cancer drugs ecosystem
  • Market drivers and barriers
  • Types of cancer, treatment options and key trends
  • Analysis of key drug classes and leading cancer drugs
  • Future drug development pipeline
  • Industry roadmap and value chain
  • Profiles and strategies of 100 leading ecosystem players, including cancer drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2016 till 2030
Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Pathways
    • Immuno-Oncology & Targeted Therapies
    • Cytotoxic & Hormonal Therapies
  • Therapeutic Categories
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Renal Cancer
    • Skin Cancer
    • Other Cancers
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the cancer drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in oncology?
  • How big is the market for immuno-oncology and targeted cancer therapies?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should cancer drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AbbVie
AbGenomics International
Actelion Pharmaceuticals
Active Biotech
Adaptimmune Therapeutics
Adimab
Aduro Biotech
Advantagene
Allergan
Amgen
ARIAD Pharmaceuticals
ArQule
Array BioPharma
Astellas Pharma
AstraZeneca
Baxalta
Baxter International
Bayer
BioLineRx
Biomunex Pharmaceuticals
Bionovo
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Caladrius Biosciences
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics
Cellectics
Celsion Corporation
Clovis Oncology
CTI Biopharma Corporation
CureTech
Daiichi Sankyo
Dr. Reddy's Laboratories
Eagle Pharmaceuticals
Eisai
Eli Lilly & Company
Exelixis
Galena Biopharma
Geron Corporation
Gilead Sciences
Globeimmune
GSK (GlaxoSmithKline)
Helsinn
Immune Pharmaceuticals
ImmunoGen
Infinity Pharmaceuticals
Intrexon Corporation
Ipsen
Janssen Pharmaceutical Companies
Johnson & Johnson
Juno Therapeutics
Kite Pharma
Kura Oncology
Les Laboratoires Servier
Loxo Oncology
MacroGenics
Massachusetts General Hospital
Medivation
MEI Pharma
Merck & Co.
Merck KGaA
Merrimack Pharmaceuticals
Millennium
MIT (Massachusetts Institute of Technology)
Mylan
NanoString Technologies
Nektar Therapeutics
NewLink Genetics
NHS (National Health Service, UK)
Novartis
NTU (Nanyang Technological University)
OncoGenex Pharmaceuticals
OncoMed Pharmaceuticals
Oncothyreon
Onxeo
Otsuka Holdings
Peregrine Pharmaceuticals
Pfizer
PharmaMar
Photocure
Precision BioSciences
Principia Biopharma
Provectus Biopharmaceuticals
Puma Biotechnology
Radius Health
Redx Pharma
Regeneron Pharmaceuticals
Roche Holding (F. Hoffmann-La Roche)
Sanofi
Sentinel Oncology
SINTEF 
Sumitomo Dainippon Pharma
Sun Pharma (Sun Pharmaceutical Industries)
Sunesis Pharmaceuticals
Symphogen
Syndax Pharmaceuticals
Taiho Oncology
Taiho Pharmaceutical
Takeda Pharmaceutical Company
Tesaro
Teva Pharmaceutical Industries
Threshold Pharmaceuticals
U.S. FDA (Food and Drug Administration)
United Therapeutics Corporation
Vaccinogen
VBL therapeutics
Verastem
Viventia Bio
X4 Pharmaceuticals
ZIOPHARM Oncology
Comments